🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 135 of 857 · Phase 3 first, then by program name

  1. Pemetrexed 500mg/m2 iv

    Hospital Authority, Hong Kong

    NSCLC

    phase 3 small molecule active

    1 trial

  2. Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, TAGRISSO 40 mg film-coated tablets, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 100 mg powder for concentrate for solution for infusion, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. Pemigatinib

    Incyte

    Unresectable Cholangiocarcinoma

    phase 3 small molecule terminated

    1 trial

  4. Pentoxifylline

    United Therapeutics Europe Ltd

    Kidney Failure, Chronic

    phase 3 small molecule completed

    1 trial

  5. Peramivir

    Biocryst

    Seasonal Influenza

    phase 3 small molecule completed

    1 trial

  6. Peramivir

    Biocryst

    Influenza

    phase 3 small molecule completed

    5 trials

  7. Peramivir 150mg

    Biocryst

    Influenza

    phase 3 small molecule terminated

    1 trial

  8. Peramivir+SOC

    Biocryst

    Cough

    phase 3 small molecule terminated

    1 trial

  9. Pergolide

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 3 small molecule completed

    1 trial

  10. Permethrin, InfectoScab® 5 % Crème

    Alphapharm Pty Ltd

    Scabies

    phase 3 small molecule active

    1 trial

  11. Phase 1: Olanzapine

    Shanghai Mental Health Center

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  12. Phase 2; Low Dose MYOBLOC

    SUPERNUS PHARMACEUTICALS, INC.

    Spasticity

    phase 3 small molecule active

    1 trial

  13. Phase 2; Low Dose MYOBLOC (15,000 Units)

    SUPERNUS PHARMACEUTICALS, INC.

    Spasticity

    phase 3 small molecule terminated

    1 trial

  14. Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Lenalidomide with a Non-Randomized, Single Arm US Extension of Mosunetuzumab in Combination with Lenalidomide in Patients with Follicular Lymphoma After at Least One Line of Systemic Therapy

    Hoffmann-La Roche

    Relapsed/refractory follicular lymphoma

    phase 3 other active

    1 trial

  15. Phenazopyridine Hydrochloride

    Amneal Pharma Europe Ltd

    Pain

    phase 3 small molecule completed

    1 trial

  16. Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Phesgo 600 mg/600 mg solution for injection, Herceptin 150 mg powder for concentrate for solution for infusion

    Hoffmann-La Roche

    HER2-POSITIVE EARLY BREAST CANCER

    phase 3 small molecule active

    1 trial

  17. Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Phesgo 600 mg/600 mg solution for injection

    Fondazione Telethon ETS

    Invasive Breast Cancer

    phase 3 small molecule active

    1 trial

  18. Phesgo 600 mg/600 mg solution for injection, Herceptin 600 mg solution for injection in vial, Perjeta 420 mg concentrate for solution for infusion, Phesgo 1200 mg/600 mg solution for injection, Kadcyla 160 mg powder for concentrate for solution for infusion.

    Hoffmann-La Roche

    Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  19. Phlebotomy

    Atrium Therapeutics

    Hemochromatosis

    phase 3 other completed

    1 trial

  20. Phlebotomy and erythrocytapheresis

    Atrium Therapeutics

    Hereditary Hemochromatosis

    phase 3 other active

    1 trial

  21. Physiotherapy

    United Therapeutics Europe Ltd

    Sciatica

    phase 3 other completed

    1 trial

  22. Picosulfate sodium, magnesium oxide, citric acid

    Universal Integrated

    Bowel Preparation Before Colonoscopy

    phase 3 small molecule completed

    1 trial

  23. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Irritability Associated With Autism Spectrum Disorder

    phase 3 small molecule completed

    2 trials

  24. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Adjunctive Treatment of Major Depressive Disorder

    phase 3 small molecule terminated

    3 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources